BAN1202
Parkinson's Disease
PreclinicalProprietary program
Key Facts
About BioArctic AB
BioArctic is a publicly traded Swedish biotech company at the forefront of developing novel treatments for neurodegenerative disorders. Its most significant achievement is the co-development of lecanemab (Leqembi®) with Eisai, which became the first amyloid-targeting therapy to receive traditional FDA approval for Alzheimer's disease. The company leverages its proprietary BrainTransporter® technology to develop antibodies and other biologics that can cross the blood-brain barrier, with a pipeline extending beyond Alzheimer's to Parkinson's disease and other CNS conditions. BioArctic's strategy combines proprietary research with strategic partnerships to advance its clinical programs.
View full company profileTherapeutic Areas
Other Parkinson's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| ABBV-951 | AbbVie | Phase 3 |
| UCB0107 | UCB | Phase 1 |
| Stalevo | Orion Corporation | Approved |
| Comtan/Comtess | Orion Corporation | Approved |
| CHRONOS-PD Platform | Grifols | Research |
| GT-001 (Gene Therapy) | Sumitomo Pharma | Phase 1/2 |
| CREXONT (Carbidopa/Levodopa) | Amneal Pharmaceuticals | Approved |
| BIIB122/DNL151 | Denali Therapeutics | Phase 3 |
| ABBV-0805 | BioArctic AB | Phase 1 |
| ARV-102 | Arvinas | Phase 1 |
| AAV-GAD | MeiraGTx | Preclinical/Phase 1 |
| Not Specified | Minerva Neurosciences | Clinical Stage |